2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, 97.0%, 100g

1-Oxo-1H-isochromene-4-carboxylic acid, 95.0%, 250mg

8-Methyl-1,2,3,4-tetrahydroquinoline, 95.0%, 5g

Sal disódica de magnesio EDTA x H2O, mínimo 90%, para síntesis, 500 g, envase de plástico.

(E)-Ethyl 3-(1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acrylate, 98%, 100mg

(2S,3R)-1-[(tert-Butoxy)carbonyl]-3-fluoropyrrolidine-2-carboxylic acid, 97%, 100mg

3-(3,3-Difluorocyclobutyl)propanoic acid, 98%, 5g

N-(4-Aminopyridin-2-yl)acetamide, 95.0%, 250mg

AEBSF Inhibidor de Proteasa 1g

(S)-5-((Trityloxy)methyl)pyrrolidin-2-one, 97%, 1g

2-Bromobicyclo[2.2.1]heptane, 97.0%, 5g

Pentadecane>99.0%(GC)25mL

4-(Dimethylamino)phenol hydrochloride, 95.0%, 1g